Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03520582
Other study ID # 16.22.CLI
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date November 6, 2017
Est. completion date July 30, 2018

Study information

Verified date September 2018
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to evaluate the technical feasibility of the new tube placement technology in healthy volunteers and, if proven feasible, in critically ill patients requiring placement of a feeding tube.


Description:

Enteral feeding is the preferred route of nutrient delivery in hospitalized patients who cannot eat sufficiently. Placement of enteral feeding tubes carries a risk of misplacement especially in patients who are unable to fully collaborate during the tube placement due to neurological impairment and/or the presence of an artificial airway. The misplacement of a feeding tube in the airways has a high risk of severe complications, including pneumonia, mechanical damage of airways and the lung, and death. The verification of correct tube placement can be done using radiography, or interventions aimed at confirming the location of the tube tip by aspiration of gastric contents, and by auscultation during injection of air.

Approximately 20-25 % of patients treated in intensive care units are likely to need placement of a feeding tube, while undergoing mechanical ventilation and having an artificial airway. This high risk patient group would benefit from technologies allowing direct visualization of tube placement. It is also expected that direct visualization of tube placement will allow confirmation of tube placement and therefore eliminate the need of radiography (radiation).


Recruitment information / eligibility

Status Terminated
Enrollment 12
Est. completion date July 30, 2018
Est. primary completion date June 7, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

Healthy volunteers

- Informed Consent as documented by signature (Appendix Informed Consent Form)

- Age >18 years

Patients

- Age >18 years

- mechanically ventilated and requiring a placement of a postpyloric feeding tube on clinical indications

- Informed Consent as documented by signature of relatives

Exclusion Criteria:

Healthy volunteers and patients

- Unrepaired tracheoesophageal fistula

- history of prior esophageal or gastric surgery

- esophageal obstruction, stricture, varices or diverticulum

- esophageal or gastric perforation, gastric or esophageal bleeding

- recent oropharyngeal surgery

- cervical spine injury or anomaly

Additional exclusion criterion for patients only

• know severe coagulopathy (defined as thrombocyte count less than 30x10e9/l or International Normalized Ratio (INR) > 3)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Tube placement
Placement of enteral feeding tubes

Locations

Country Name City State
Switzerland Universitätsklinik für Intensivmedizin Bern

Sponsors (1)

Lead Sponsor Collaborator
Nestlé

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Success rate of postpyloric placement, time to reach intragastric and postpyloric position, ease of insertion, handling and image quality. using a visual analog scale of 1-10, with 1 indicating the best value During Intervention Visit, an average of 24 hours
Secondary In healthy volunteers, time required to reach gastric and postpyloric placement Questionnaire with various positions and the time to reach the position During Intervention Visit, an average of 24 hours
Secondary In healthy volunteers, ease of insertion, handling, and image quality assessed Using a visual analog scale of 1-10, with 1 indicating the best value During Intervention Visit, an average of 24 hours
Secondary In healthy volunteers, Usability of specific features - tip steerability, lens rinsing and flushing, air insufflation and fluid extraction Using a visual analog scale of 1-10, with 1 indicating the best value. During Intervention Visit, an average of 24 hours
Secondary In patients: Necessity of use of additional sedation/analgesia for the procedure in addition to already established sedation in the context of mechanical ventilation. Questionnaire Yes/No and a visual analog scale of 1-10, with 1 indicating the best value During Intervention Visit, an average of 24 hours
Secondary In patients: Ease of insertion, handling, and image quality assessed using a visual analog scale of 1-10, with 1 indicating the best value. using a visual analog scale of 1-10, with 1 indicating the best value During Intervention Visit, an average of 24 hours
Secondary In patients: Usability of specific features - tip steerability, lens rinsing and flushing, air insufflation and fluid extraction. using a visual analog scale of 1-10, with 1 indicating the best value During Intervention Visit, an average of 24 hours
Secondary In patients: Subjective global assessment of the intensivist on whether or not the technique is suitable for clinical use in patients. using a visual analog scale of 1-10, with 1 indicating the best value During Intervention Visit, an average of 24 hours
Secondary In patients: Time required to reach gastric and postpyloric placement Questionnaire During Intervention Visit, an average of 24 hours
Secondary In patients: Feasibility of the feeding through Veritract tube. using a visual analog scale of 1-10, with 1 indicating the best value During Intervention Visit, an average of 24 hours
Secondary Bleeding and infection related to tube placement AE/SAE Questionnaire Yes/No During Intervention Visit, an average of 24 hours
Secondary Erroneous placement in larynx and trachea and associated complications (pneumothorax). Outcome mesured with a questionnaire Yes/No During Intervention Visit, an average of 24 hours
Secondary Injuries of the oesophagus, stomach or small intestine related to tube placement. Outcome mesured with a questionnaire Yes/No During Intervention Visit, an average of 24 hours
Secondary Reflux of stomach contents during tube placement AE/SAE Questionnaire Yes/No During Intervention Visit, an average of 24 hours
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1